New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections

Current Opinion in Critical Care

Volumn 21, Issue 5, 2015, Pages 402-411

  Bassetti, Matteo ^a   Righi, Elda ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

combination regimens; gram negative pathogens; multidrug resistance; new antibiotics

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AVIBACTAM; AZTREONAM; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; COLISTIN; ERAVACYCLINE; ERTAPENEM; FOSFOMYCIN; IMIPENEM; MEROPENEM; PANIPENEM; PLAZOMICIN; RAZUPENEM; RELEBACTAM; SULBACTAM; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOMOPENEM; UNINDEXED DRUG; VABORBACTAM;

ACINETOBACTER BAUMANNII; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); GRAM NEGATIVE INFECTION; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; REVIEW; COMBINATION DRUG THERAPY; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

EID: 84959557515     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000235     Document Type: Review

References (103)

1. Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant gramnegative bacilli in the United States. Infect Control Hosp Epidemiol 2010; 31: S51-54
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12
3. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamaseproducing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clinic Proceed Mayo Clinic 2011; 86: 250-259
4. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012; 18: 439-448
5. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. J Am Med Assoc 2008; 300: 2911-2913
6. Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant Gramnegative pathogens. Infect Chemother 2014; 46: 149-164
7. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Ag Chemother 1995; 39: 1211-1233
8. Hammerum AM, Toleman MA, Hansen F, et al. Global spread of New Delhi metallo-beta-lactamase 1. Lancet Infect Dis 2010; 10: 829-830
9. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53: 60-67
10. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-796
11. Piddock LJ. The crisis of no new antibiotics: what is the way forward? Lancet Infect Dis 2012; 12: 249-253
12. Infectious Diseases Society of A. The 10 x 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-1083
13. Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19: E23-30
14. Skiada A, Markogiannakis A, Plachouras D, Daikos GL. Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. Int J Antimicrob Ag 2011; 37: 187-193; 15.16
15. Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multicentre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20: O117-123
16. Qureshi ZA, Paterson DL, Peleg AY, et al. Clinical characteristics of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in the era of CTX-M-Type and KPC-Type beta-lactamases. Clin Microbiol Infect 2012; 18: 887-893
17. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-950
18. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56: 398-404
19. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Ag Chemother 2012; 56: 4241-4249
20. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Ag Chemother 2009; 53: 3430-3436
21. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-884
22. Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013; 17: R174
23. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-T-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Ag Chemother 1999; 43: 738-744
24. Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Ag Chemother 2011; 55: 390-394
25. Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multidrug resistant gram-negative pathogens. J Infect 2009; 58: 273-284
26. De Pascale G, Montini L, Spanu T, et al. High-dose tigecycline use in severe infections. Presented at: 33rd International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium, 19-22 March, 2013
27. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-236
28. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Ag Chemother 2014; 58: 5598-5601
29. Parker S, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Ag 2013; 42: 289-293
30. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Ag 2014; 43: 52-59
31. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012; 25: 450-470
32. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-Associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35: 1888-1895
33. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Inf Dis 2011; 17: 1798-1803
34. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Inf Dis 2014; 33: 1311-1322
35. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-(-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-187322
36. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349-358
37. Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrugresistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Inf Dis 2012; 31: 695-701
38. Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Inf 2014; 20: 862-872
39. Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012; 24: 191-194
40. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the nextgeneration aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Exp Rev Antiinfect Ther 2012; 10: 459-473
41. Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Ag Chemother 2011; 55: 5874-5880
42. Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Exp Opin Pharmacother 2013; 14: 1585-1597
43. ClinicalTrial.org. A study of plazomicin compared with colistin in patients with infection due to carbapenem-resistant Enterobacteriaceae (CRE). Identifier NCT01970371
44. Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, nonbeta-lactam beta-lactamase inhibitor. Proce Natl Acad Sci USA 2012; 109: 11663-11668
45. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-Avibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers. Antimicrob Ag Chemother 2013; 57: 3299-3306
46. Levasseur P, Girard AM, Miossec C, et al. In vitro antibacterial activity of the ceftazidime-Avibactam combination against Enterobacteriaceae, including strains with well characterized beta-lactamases. Antimicrob Ag Chemother 2015; 59: 1931-1934
47. Vazquez JA, Gonzalez Patzan LD, Stricklin D, et al. Efficacy and safety of ceftazidime-Avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28: 1921-1931
48. Lucasti C, Popescu, I, Ramesh, M, et al. Efficacy and safety of ceftazidime/NXL104 plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults. Presented at: European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy. Milan, Italy, 7-10 May 2011
49. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Ag Chemother 2005; 49: 3501-3512
50. ClinicalTrials.gov. Pharmacokinetic study of ceftaroline fosamil/avibactam in adults with augmented renal clearance. Identifier N. NCT01624246
51. Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-Avibactam and aztreonam-Avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Ag Chemother 2014; 58: 1774-1778
52. ClinicalTrials.gov. To investigate the safety and tolerability of aztreonamavibactam (ATM-AVI). Identifier N. NCT01689207
53. Hirsch EB, Ledesma KR, Chang KT, et al. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenemresistant Gram-negative bacteria. Antimicrob Ag Chemother 2012; 56: 3753-3757
54. ClinicalTrials.gov. Study of the safety, tolerability, and efficacy of MK-7655 imipenem/cilastatin versus imipenem/cilastatin alone for the treatment of complicated urinary tract infection (cUTI) (MK-7655-003). NCT01275170
55. ClinicalTrials.gov. Study of the safety, tolerability, and efficacy of MK-7655 imipenem/cilastatin versus imipenem/cilastatin alone to treat complicated intra-Abdominal infection [cIAI] (MK-7655-004). NCT01506271
56. Castanheira M, Becker HK, Rhomberg PR, Jones RN. Effect of the blactamase inhibitor RPX7009 combined with meropenem tested against a large collection of KPC-producing Enterobacteriaceae. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, 5-9 September 2014, Washington, United States
57. ClinicalTrials.gov. A phase 3, multi-center, randomized, open-label study of carbavance (Meropenem/RPX7009) versus best available therapy in subjects with selected serious infections due to carbapenem-resistant Enterobacteriaceae. Identifier N. NCT02168946
58. ClinicaTrials.gov. A phase 3, multi-center, randomized, open-label study of carbavance (Meropenem/RPX7009) versus best available therapy in subjects with selected serious infections due to carbapenem-resistant Enterobacteriaceae. Identifier N. NCT02168946
59. Chen HY, Livermore DM. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J Antimicrob Chemother 1994; 33: 949-958
60. Jia B, Lu P, Huang W, et al. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemother 2010; 56: 285-290
61. Perry CM, Ibbotson T. Biapenem Drugs 2002 62 2221-2234. [discussion 2235]
62. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Ag Chemother 2010; 54: 565-569
63. Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a doublecarbapenem regimen for infections in humans due to carbapenemaseproducing pandrug-resistant Klebsiella pneumoniae. Antimicrob Ag Chemother 2013; 57: 2388-2390
64. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Ag Chemother 2011; 55: 3002-3004
65. Ceccarelli G, Falcone M, Giordano A, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-Associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Ag Chemother 2013; 57: 2900-2901
66. Thomson KS. Double-carbapenem therapy not proven to be more active than carbapenem monotherapy against KPC-positive Klebsiella pneumoniae. Antimicrob Ag Chemother 2012; 56: 4037. [author reply 4038]
67. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Therapeut 2009; 31: 42-63
68. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Ag Chemother 2011; 55: 4943-4960
69. Goa KL, Noble S. Panipenem/betamipron drugs 2003 63 913-925. [discussion 926]
70. MacGowan AP, Noel A, Tomaselli S, et al. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection. Antimicrob Ag Chemother 2011; 55: 1436-1442
71. Livermore DM, Mushtaq S, Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 2009; 64: 330-335
72. Tran CM, Tanaka K, Yamagishi Y, et al. In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria. Antimicrob Ag Chemother 2011; 55: 2398-2402
73. Sato N, Kijima K, Koresawa T, et al. Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug Met Pharmacokin 2008; 23: 434-446
74. Koga T, Abe T, Inoue H, et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 2005; 49: 3239-3250
75. Sugihara K, Sugihara C, Matsushita Y, et al. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. Antimicrob Agents Chemother 2010; 54: 5298-5302
76. Breilh D, Texier-Maugein J, Allaouchiche B, et al. Carbapenems. J Chemother 2013; 25: 1-17
77. Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 3933-3937
78. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011; 55: 2390-2394
79. Juan C, Zamorano L, Perez JL, et al. Spanish Network for Research in Infectious D: activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Ag Chemother 2010; 54: 846-851
80. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013; 75: 304-307
81. Clinicaltrials.gov. Study comparing the safety and efficacy of intravenous CXA-201 and intravenous levofloxacin in complicated urinary tract infection, including pyelonephritis. Identifier NCT01345929
82. Wagenlehner F, Umeh O, Huntington J, et al. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (CUTI)/pyelonephritis in hospitalised adults: results from the phase 3 aspect-CUTI trial. Presented at 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 10-13 May 2014
83. Clinicaltrials.gov. Study comparing the safety and efficacy of intravenous CXA-201 and intravenous meropenem in complicated intraabdominal infections. Identifier NCT01445678
84. Eckmann C, Hershberger E, Miller B, et al. Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-Abdominal infections (cIAI) in hospitalised adults: results from the phase 3 aspectcIAI trial. Presented at 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, May 10-13, 2014 Presents the results of the phase 3 trials in cIAIs comparing ceftolozane/tazobactam versus meropenem
85. Queenan AM, Shang W, KaniaM, et al. Interactions of ceftobiprole with betalactamases from molecular classes A to D. Antimicrob Ag Chemother 2007; 51: 3089-3095
86. Walkty A, Adam HJ, Laverdiere M, et al. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gramnegative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69: 348-355
87. Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-Acquired pneumonia requiring hospitalisation. Int J Antimicrob Ag 2012; 39: 240-246
88. Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010; 65 (Suppl 4): iv9-16
89. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis ofCANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-650
90. Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Ther 2012; 67: 2814-2820
91. Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Ag Chemother 2003; 47: 3260-3269
92. Almer LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 2004; 48: 2771-2777
93. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the antigram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Ag Chemother 2011; 55: 649-658
94. Stubbings W, Leow P, Yong GC, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-Activated fluoroquinolone, under standard and acidic conditions. Antimicrob Ag Chemother 2011; 55: 4394-4397
95. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and-resistant Acinetobacter baumannii isolates. Antimicrob Ag Chemother 2010; 54: 1613-1615
96. ClinicalTrials.gov. Finafloxacin 300mg twice a day (b.i.d.) versus ciprofloxacin 250 mg twice a day (b.i.d) in patients with lower uncomplicated UTI (uUTI) (FLUT). Identifier NCT00722735
97. ClinicalTrials.gov. A multi-dose, double-blind, double-dummy, active-control, randomized clinical (phase II) study of two dosing regimens of finafloxacin for the treatment of cUTI and/or acute pyelonephritis requiring hospitalisation. Identifier NCT01928433
98. Clark RB, Hunt DK, He M, et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem 2012; 55: 606-622
99. Sutcliffe JA, OBrien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Ag Chemother 2013; 57: 5548-5558
100. Grossman TH, Starosta AL, Fyfe C, et al. Target-And resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Ag Chemother 2012; 56: 2559-2564
101. Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-Acquired complicated intra-Abdominal infections. Antimicrob Ag Chemother 2014; 58: 1847-1854
102. Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Ag Chemother 2014; 58: 1127-1135
103. Robert D, Arbeit DR, Roberts JA, et al. Safety and efficacy of PTK 0796: results of the phase 2 study in complicated skin and skin structure infections following IV and oral step down therapy. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 2014